Skip to main content

Table 4 Main findings (secondary outcomes).

From: Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis

  Angina Heart failure Diabetes incidence
Diuretics vs. BB 0.96 (0.28 to 5.78) 0.73 (0.54 to 0.96) 1.09 (0.80 to 1.44)
  OOO O OO
Diuretics vs. ACE 0.97 (0.42 to 2.51) 0.88 (0.76 to 1.06) 1.43 (1.12 to 1.83)
  OO OO O
Diuretics vs. CCB 1.05 (0.56 to 2.19) 0.73 (0.62 to 0.84) 1.27 (1.05 to 1.57)
  OO O
Diuretics vs. alpha-blockers 0.89 (0.31 to 2.52) 0.51 (0.40 to 0.64) -
  OOO O  
Diuretics vs. ARB 0.86 (0.39 to 3.27) 0.80 (0.61 to 0.98) 1.59 (1.23 to 2.12)
  OOO OO OO
BB vs. ACE 1.03 (0.17 to 3.76) 1.21 (0.91 to 1.69) 1.31 (0.95 to 1.88)
  OOO OOO OOO
BB vs. CCB 1.10 (0.23 to 3.31) 1.00 (0.76 to 1.33) 1.17 (0.89 to 1.61)
  OOO OOO OOO
BB vs. alpha-blockers 0.93 (0.11 to 4.35) 0.69 (0.50 to 1.02) -
  OOO OOO  
BB vs. ARB 0.88 (0.31 to 2.58) 1.08 (0.86 to 1.38) 1.46 (1.15 to 1.98)
  OO
ACE vs. CCB 1.08 (0.48 to 2.44) 0.82 (0.69 to 0.94) 0.89 (0.73 to 1.10)
  OOO O OO
ACE vs. alpha-blockers 0.91 (0.22 to 3.42) 0.58 (0.43 to 0.75) -
  OOO OO  
ACE vs. ARB 0.86 (0.35 to 3.50) 0.90 (0.67 to 1.10) 1.11 (0.85 to 1.51)
  OOO OOO OOO
CCB vs. alpha-blockers 0.85 (0.23 to 2.78) 0.70 (0.53 to 0.92) -
  OOO OO  
CCB vs. ARB 0.81 (0.45 to 2.30) 1.10 (0.87 to 1.31) 1.25 (1.02 to 1.56)
  OO O
Alpha-blockers vs. ARB 0.95 (0.29 to 5.71) 1.57 (1.09 to 2.12) -
  OOO OO  
  1. ACE, Angiotensin Converting Enzyme Inhibitors; ARB, Angiotensin Receptor Blockers; BB, Beta-blockers; CCB, Calcium Channel Blockers; , High quality evidence; O, Moderate quality evidence; OO, Low quality evidence; OOO, Very low quality evidence